AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20598621
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of symptomatic therapy
Trial: 18036365
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day rosuvastatin
Trial: 8623801
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized dehydroepiandrosterone 300 mg
Trial: 8623801
Drug: Oral crystalline
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral crystalline dehydroepiandrosterone 300 mg
Trial: 8623801
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized dehydroepiandrosterone 150 mg
Trial: 8623801
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized dehydroepiandrosterone 150 mg
Trial: 1952858
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil at 250 mg
Trial: 1952858
Drug: Cefaclor at
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor at 250 mg
Trial: 1952858
Drug: Cefaclor at
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor at 375 mg
Trial: 1952858
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil at 250 mg and cefaclor at 375 mg twice daily or cefaclor at 250 mg three times daily
Trial: 7039204
Drug: Cimetidine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1.2 grams daily for 35 days)
Trial: 31433518
Drug: Zoledronate (ZOL)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate (ZOL) 5 mg infusion
Trial: 31433518
Drug: Denosumab (Dmab)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab (Dmab) 60 mg injections (2 additional injections)
Trial: 29970736
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (Group A) 1 mg/kg for two weeks
Trial: 29970736
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone (Group B) 30 mg/kg for three days followed by oral prednisolone 1 mg/kg for two weeks
Trial: 22774791
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Cognitive Therapy + Antidepressant medication)
Trial: 20716770
Drug: Zosuquidar (550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zosuquidar (550 mg)
Trial: 12422079
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (ampicillin/sulbactam, 25 mg/kg/daily)
Trial: 12422079
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment combined with intranasal budesonide (200 mg/daily)
Trial: 11938741
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg administered intravenously)
Trial: 11938741
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no diazepam administered)
Trial: 2046138
Drug: CV-4151 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV-4151 (selective inhibitor of thromboxane A2 synthetase), administered greater than or equal to 2 days before angioplasty and continued until follow-up (3-6 months after angioplasty)
Trial: 28650194
Drug: Internet-delivered parent-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered parent-child interaction therapy (I-PCIT)
Trial: 28650194
Drug: clinic-based parent-child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinic-based parent-child interaction therapy (PCIT)
Trial: 26076571
Drug: Chronic glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic glucose metabolism disorders (A)
Trial: 19549020
Drug: 1,800 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,800 mg/d EPA-DHA (n=96)
Trial: 19549020
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d EPA-DHA (n=100)
Trial: 19549020
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (n=106)
Trial: 10799351
Drug: Octreotide 200
RxNorm normalized name: octreotide 200 mcg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 200 microgram s.c. 3 times daily, starting the night before endoscopic procedures
Trial: 10799351
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 times daily, starting the night before endoscopic procedures
Trial: 1381640
Drug: Teicoplanin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin, 400 mg i.v., given as a single dose
Trial: 16122283
Drug: Crushed moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with water (regimen B)
Trial: 16122283
Drug: Crushed moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed moxifloxacin 400 mg tablet as a suspension through a nasogastric tube with enteral feeding (regimen C)
Trial: 16122283
Drug: Intact moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact moxifloxacin 400 mg tablet (regimen A, reference treatment)
Trial: 10402079
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 30 mg ketoprofen plaster (n = 40)
Trial: 10402079
Drug: Multiple applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple applications of 30 mg ketoprofen plaster for 5 days (n = 30)
Trial: 10402079
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 50 mg ketoprofen (n = 30)
Trial: 7594331
Drug: Lansoprazole injection
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole injection 30 mg once daily
Trial: 7594331
Drug: Lansoprazole injection
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole injection 30 mg twice daily
Trial: 7594331
Drug: Lansoprazole injection
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole injection 15 mg twice daily
Trial: 7594331
Drug: Histamine H2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H2-receptor antagonist 20 mg twice daily
Trial: 22182865
Drug: Continuous intercostal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intercostal nerve block (CINB) with 0.2% ropivacaine infusion
Trial: 14759615
Drug: Cyclofem (medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclofem (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Trial: 14759615
Drug: NET-EN (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NET-EN (norethisterone enanthate 200 mg)
Trial: 11772793
Drug: Preoperative thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative thoracic epidural analgesia (TEA) with bupivacaine and morphine solution, postoperative epidural PCA
Trial: 11772793
Drug: Postoperative thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative thoracic epidural analgesia (TEA) with bolus dose
Trial: 11772793
Drug: IV patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV patient‐controlled analgesia (IV‐PCA) with morphine
Trial: 9690692
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/day (group 1)
Trial: 9690692
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg/day (group 2)
Trial: 2668978
Drug: Minaprine 400
RxNorm normalized name: minaprine
DrugBank: Minaprine (DB00805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine 400 mg daily
Trial: 403395
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with radiotherapy (5000 rads) and ICRF 159 (250 mg p.d.)
Trial: 403395
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with radiotherapy and ICRF 159
Trial: 27629581
Drug: Risk Reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk Reduction Therapy for Adolescents (RRTA)
Trial: 27136912
Drug: Fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 500 mg under high-fat breakfast conditions
Trial: 27136912
Drug: Fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 500 mg under low-fat breakfast conditions
Trial: 27136912
Drug: Fedratinib 100
RxNorm normalized name: fedratinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fedratinib 100 mg under high-fat breakfast conditions
Trial: 27136912
Drug: Fedratinib 500
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 500 mg under fasted conditions
Trial: 23873570
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination with 125 µg OMP alone
Trial: 23873570
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination with OMP+NP
Trial: 23873570
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination with OMP only
Trial: 23873570
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination with or without NP
Trial: 23873570
Drug: Subcutaneous vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vaccination with 125 µg OMP alone and OMP+NP
Trial: 19371311
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion at 30 microg min(‐1)
Trial: 19371311
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion at 100 microg min(‐1)
Trial: 19371311
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion at 50 microg min(‐1)
Trial: 19371311
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with antihistamines pretreatment
Trial: 19371311
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with nitric oxide clamp
Trial: 10696747
Drug: Subconjunctival mydricaine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival mydricaine and topical diclofenac 0.1%
Trial: 3492759
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trimethoprim twice a day
Trial: 3492759
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg trimethoprim plus 800 mg sulphamethoxazole twice a day
Trial: 22732846
Drug: Sublingual ketorolac
RxNorm normalized name: ketorolac Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual ketorolac (10 mg 4 times daily)
Trial: 22732846
Drug: Sublingual piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual piroxicam (20 mg once daily)
Trial: 9523857
Drug: Drinking water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking water with less than 1.57 micromol/l (<0.1 mg/l)
Trial: 9523857
Drug: Drinking water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking water with 31.48 micromol/l (2 mg/l) of copper
Trial: 2568660
Drug: Triprolidine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triprolidine (7.5 mg)
Trial: 798330
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone therapy at the time of kidney transplantation
Trial: 31448392
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections (triamcinolone in 2% xylocaine)
Trial: 20591206
Drug: Very-long-chain inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very-long-chain inulin (VLCI) 10 g/d
Trial: 20591206
Drug: Maltodextrin (placebo)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin (placebo) 10 g/d
Trial: 8578060
Drug: Gabapentin as
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin as add-on therapy; different dosages not specified.
Trial: 6123647
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (assumed benefit for rapid growth stratum)
Trial: 29229000
Drug: Self-administered, computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered, computerized SBIRT intervention
Trial: 29229000
Drug: Clinician-administered SBIRT
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-administered SBIRT intervention
Trial: 17570119
Drug: Vicriviroc 5
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 5 mg
Trial: 17570119
Drug: Vicriviroc 10
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 10 mg
Trial: 17570119
Drug: Vicriviroc 15
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc 15 mg
Trial: 10546931
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg of intravitreal TPA in buffered salt solution (BSS) 15 minutes before vitrectomy
Trial: 7477217
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of oral lamivudine daily for 12 weeks
Trial: 7477217
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of oral lamivudine daily for 12 weeks
Trial: 7477217
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of oral lamivudine daily for 12 weeks
Trial: 7477217
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg or 300 mg of oral lamivudine daily for 12 weeks
Trial: 2124651
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain amino acid (BCAA) administration postoperatively in gastrectomized rats and in humans after subtotal or total gastrectomy.
Trial: 2124651
Drug: Conventional total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional total parenteral nutrition with a Calorie/N ratio of about 150.
Trial: 7047460
Drug: Aspirin (acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (acetylsalicylic acid)
Trial: 18240868
Drug: PEG‐IFN‐α2b monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐α2b monotherapy
Trial: 15110370
Drug: Fentanyl (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.7 microg/kg bolus in 2-mL balanced salt solution)
Trial: 15110370
Drug: Control (2-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2-mL balanced salt solution without analgesic)
Trial: 9093341
Drug: Flow triggering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow triggering (1 and 5 l/min) during pressure support ventilation (PSV) and assisted controlled mode (A/C)
Trial: 9093341
Drug: Flow triggering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow triggering (1 and 5 l/min) in A/C mode
Trial: 10171655
Drug: Plasmapheresis for
RxNorm normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis for the production of platelet rich plasma (PRP), 20% of circulating plasma volume sequestered prior to heparinization, reinfused 10 minutes after heparin reversal.
Trial: 3759280
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day atenolol
Trial: 3759280
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day mepindolol
Trial: 21849282
Drug: Inactivated 2009
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated 2009 H1N1 influenza vaccine (25 μg)
Trial: 21849282
Drug: Inactivated 2009
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated 2009 H1N1 influenza vaccine (49 μg)
Trial: 11321866
Drug: Doxazosin included
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin included in 'tight control' combination therapy
Trial: 24829298
Drug: Standard PN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PN solution without taurine (control PN)
Trial: 22741449
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 mg once daily
Trial: 19256268
Drug: Factors related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors related to surgery and pharmacological treatment
Trial: 15625257
Drug: Diclectin (DCL)
RxNorm normalized name: PYRITHIONE ZINC 4.63 g in 236 mL TOPICAL LOTION/SHAMPOO [DCL Zoma]
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diclectin (DCL) administered orally (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) the night before surgery, the morning of surgery, and upon hospital discharge.
Trial: 14658924
Drug: Ritalin LA
RxNorm normalized name: Ritalin LA
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritalin LA (10-40 mg/day)
Trial: 8867198
Drug: Full cognitive‐behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full cognitive‐behavioural treatment programme (CBT)
Trial: 6234282
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg 12 hourly)
Trial: 6234282
Drug: Nalidixic acid/citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalidixic acid/citrate (1 sachet 8 hourly)
Trial: 31340804
Drug: CBT‐i-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT‐i-based group treatment (10 weekly 90-min group sessions and scheduled telephone support)
Trial: 29414142
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) - one standardized Behavioral Health Consultation visit followed by three ACT-based group visits and one group booster visit.
Trial: 29414142
Drug: Enhanced Treatment
RxNorm normalized name: Thera-M Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment as Usual (E-TAU) - educational pain management handouts based on standard cognitive behavioral treatment of pain.
Trial: 22170358
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid (400 μg) + vitamin B-12 (100 μg) supplementation
Trial: 17944890
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle (PFM) and fitness exercises, 60 minutes per session, twice a week for 3 months
Trial: 11992180
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus betamethasone dipropionate 0.05% cream (mid-high-potency steroid)
Trial: 11992180
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus mometasone furoate 0.1% ointment (high-potency steroid)
Trial: 11992180
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel plus diflorasone diacetate 0.05% ointment (high-potency steroid)
Trial: 11992180
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% gel alone
Trial: 9646148
Drug: Daily prayer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily prayer or Bible study